STOCK TITAN
  1. Home
  2. Sec-filings
  3. SRRK
  4. [8-K] Scholar Rock Holding Corp Reports Material Event

Scholar Rock (NASDAQ: SRRK) details Q2 loss and apitegromab FDA review

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Scholar Rock reported a Q2 2026 net loss of $109.9 million, or $0.84 per share, with no revenue for the quarter. Research and development expense was $58.2 million and general and administrative expense was $50.7 million. The company ended June 30, 2026 with $492.1 million in cash, cash equivalents, and marketable securities, reflecting $62.8 million of net proceeds from its at-the-market equity program.

The company highlighted regulatory progress for its lead SMA candidate apitegromab. Its Biologics License Application is under FDA review with a September 30, 2026 PDUFA date, supported by two fill-finish facilities and what the company describes as ample commercial supply upon approval. The EMA is reviewing a Marketing Authorisation Application and is awaiting FDA inspection classification of the Catalent Indiana facility, while Scholar Rock discusses adding a second fill-finish site. The U.S. commercial team is preparing for launch, and development continues in earlier-stage programs, including the Phase 2 OPAL trial in infants and toddlers with SMA, the newly initiated Phase 2 FORGE trial in FSHD, and a Phase 1 study of SRK-439 in healthy volunteers.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net loss Q2 2026 $109.9 million Net loss for the quarter ended June 30, 2026
Net loss per share Q2 2026 $0.84 Basic and diluted net loss per common share for Q2 2026
Research and development expense Q2 2026 $58.2 million R&D expense for the quarter ended June 30, 2026
General and administrative expense Q2 2026 $50.7 million G&A expense for the quarter ended June 30, 2026
Cash, cash equivalents and marketable securities $492.1 million Balance as of June 30, 2026
ATM program net proceeds Q2 2026 $62.8 million Net cash proceeds from the at-the-market program during Q2 2026
Total assets June 30, 2026 $523,543 thousand Total assets on the condensed consolidated balance sheet
Weighted average shares Q2 2026 130,612,734 Weighted average common shares outstanding, basic and diluted, in Q2 2026
Biologics License Application (BLA) regulatory
"Apitegromab Biologics License Application (BLA) on track for potential FDA approval"
A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.
Prescription Drug User Fee Act (PDUFA) regulatory
"by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date"
The Prescription Drug User Fee Act (PDUFA) is a law that allows drug companies to pay fees to the government to help speed up the review process for new medicines. This funding aims to ensure that important drugs reach patients faster, which can influence a company's ability to bring products to market efficiently. For investors, PDUFA-related decisions can impact drug approval timelines and company performance.
Marketing Authorisation Application (MAA) regulatory
"engaging with European Medicines Agency (EMA) on next steps for apitegromab Marketing Authorisation Application (MAA)"
An marketing authorisation application is a formal request submitted to a health regulator asking for permission to sell a new medicine or medical product in a given market. For investors it matters because approval is the regulatory ‘green light’ that allows commercial sales and revenue, while delays, additional requirements, or rejection create uncertainty about timing, costs and a product’s market potential.
myostatin inhibitor medical
"We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor"
facioscapulohumeral muscular dystrophy (FSHD) medical
"Phase 2 FORGE study evaluating apitegromab in patients with facioscapulohumeral muscular dystrophy (FSHD)"
fill-finish facility technical
"two fill-finish facilities, representing two independent paths to an FDA approval decision"
A fill-finish facility is a specialized manufacturing site where sterile drug substances or vaccines are transferred into their final containers (vials, syringes, cartridges), sealed, labeled, and packaged for distribution. It matters to investors because it is often a production bottleneck and a capital- and regulation-heavy part of the supply chain—like a bottling plant for a beverage—so its capacity, quality controls, and inspection history can affect a product’s ability to reach the market and generate revenue.
Net loss Q2 2026 $109.9 million Compared to $110.0 million in Q2 2025
Net loss per share Q2 2026 $0.84 Compared to $0.98 in Q2 2025
R&D expense Q2 2026 $58.2 million Compared to $62.4 million in Q2 2025
G&A expense Q2 2026 $50.7 million Compared to $49.7 million in Q2 2025
Cash, cash equivalents and marketable securities $492.1 million as of June 30, 2026 Compared to $367.6 million as of December 31, 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Scholar Rock (SRRK)'s key financial results for Q2 2026?
Scholar Rock reported a net loss of $109.9 million, or $0.84 per share, for Q2 2026, with no revenue. R&D expense was $58.2 million and G&A expense was $50.7 million for the quarter ended June 30, 2026.

How much cash does Scholar Rock (SRRK) have as of June 30, 2026?
As of June 30, 2026, Scholar Rock held $492.1 million in cash, cash equivalents, and marketable securities. This balance reflects $62.8 million in net cash proceeds raised during Q2 2026 through the company’s at-the-market equity program.

What is the status of apitegromab's FDA review for SMA at Scholar Rock (SRRK)?
Scholar Rock states its apitegromab BLA for SMA is under FDA review with a September 30, 2026 PDUFA date. Review includes product from both the Catalent Indiana and a second fill-finish facility, which together provide two independent paths to a potential FDA approval decision.

What are Scholar Rock (SRRK)'s ongoing clinical trials, including OPAL, FORGE, and SRK-439 studies?
Enrollment and dosing continue in OPAL, a Phase 2 SMA study in infants and toddlers. The FORGE Phase 2 FSHD trial has been initiated, targeting about 60 patients. A Phase 1 trial of SRK-439, a subcutaneous myostatin inhibitor, is ongoing in healthy volunteers.

Is Scholar Rock (SRRK) preparing for commercialization of apitegromab?
Scholar Rock reports its U.S. commercial team is prepared to launch apitegromab immediately upon FDA approval. The company cites ample supply from a second fill-finish facility and active engagement with SMA prescribers, centers of excellence, and key community meetings.

How did Scholar Rock (SRRK)'s operating expenses evolve year over year in Q2 2026?
Total operating expenses were $108.9 million in Q2 2026 versus $112.1 million a year earlier. R&D declined to $58.2 million from $62.4 million, while G&A was $50.7 million, slightly above $49.7 million in Q2 2025.
0001727196false00017271962026-08-062026-08-06

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 06, 2026

 

 

Scholar Rock Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38501

82-3750435

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

301 Binney Street

3rd Floor

 

Cambridge, Massachusetts

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (857) 259-3860

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

SRRK

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

 

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

Description

99.1

Press Release issued by the Company on August 6, 2026, furnished hereto.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Scholar Rock Holding Corporation

Date: August 6, 2026

By:

/s/ Junlin Ho

Junlin Ho

General Counsel and Corporate Secretary

 

 

Exhibit 99.1

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

•
Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date
•
FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility has been submitted; Ample supply available for commercialization upon FDA approval
•
Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026
•
Company engaging with European Medicines Agency (EMA) on next steps for apitegromab Marketing Authorisation Application (MAA); FDA inspection classification of Catalent Indiana LLC (part of Novo Nordisk) is pending
•
Initiated Phase 2 FORGE study evaluating apitegromab in patients with facioscapulohumeral muscular dystrophy (FSHD)
•
Cash, cash equivalents, and marketable securities of $492 million as of June 30, 2026; Includes $63 million in net cash proceeds from Company’s at-the-market (ATM) program
•
Management to host a conference call today at 8:00 a.m. ET

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)— August 6, 2026 — Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments.

“We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted treatment for children and adults living with SMA,” said David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock. “Backed by a strong balance sheet, our Scholar Rock team is ready to usher in the next phase of innovation for the SMA community in the U.S. immediately upon apitegromab approval.”

 

Business Highlights and Upcoming Milestones

Apitegromab

Apitegromab is an investigational fully human monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle. It is the first and only muscle-targeted therapeutic candidate in SMA to demonstrate a statistically significant and clinically meaningful benefit in a pivotal Phase 3 clinical trial (SAPPHIRE).

SMA Program

•
Apitegromab Biologics License Application (BLA) on track for potential FDA approval by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date. The FDA review of the apitegromab BLA is advancing with both the Catalent Indiana fill-finish facility and a second fill-finish facility, representing two independent paths to an FDA approval decision. At the March 2026 Type C meeting, FDA and Scholar Rock agreed to the data package required for FDA review

 

 

of the second fill-finish facility. That data package has been submitted, and Agency review of the data is progressing well. Ample supply from the second fill-finish facility is available for commercialization upon FDA approval. The FDA inspection classification of Catalent Indiana following an April 2026 general site inspection is pending.
•
U.S. Commercial team prepared to launch apitegromab upon FDA approval. The U.S. Commercial team remains active in the field with SMA prescribers and centers of excellence nationwide, furthering disease education and awareness initiatives. The Company had a significant presence at Cure SMA’s Annual SMA Conference and Annual SMA Research & Clinical Care Meeting, which was held June 23 – 28, 2026 in Orlando, FL.
•
Scholar Rock engaging with European Medicines Agency (EMA) on next steps for apitegromab Marketing Authorisation Application (MAA). The EMA is reviewing the apitegromab MAA, which includes the Catalent Indiana fill-finish facility, and is awaiting the FDA inspection classification of Catalent Indiana. In parallel, Scholar Rock is engaging with the EMA on next steps, including the potential to add the Company’s second fill-finish facility to the MAA. The Company plans to provide updated guidance on timelines for a Committee for Medicinal Products for Human Use (CHMP) opinion upon alignment with the EMA.
•
Continued robust enrollment in Phase 2 OPAL trial. Enrollment and dosing in the Phase 2 OPAL study is ongoing (NCT07047144). The OPAL study is evaluating apitegromab in infants and toddlers with SMA under two years of age who have received an approved SMN1-targeted gene therapy or who are receiving ongoing treatment with an approved SMN2-targeted therapy.
•
Subcutaneous apitegromab progressing. Scholar Rock has developed a high concentration subcutaneous formulation of apitegromab. The Company plans to engage with the FDA and EMA to align on the development path following the regulatory approvals of apitegromab for SMA.

Facioscapulohumeral Muscular Dystrophy (FSHD) Program

•
Phase 2 FORGE trial initiated. The Phase 2 randomized, double-blind, placebo-controlled trial, called FORGE, is expected to enroll approximately 60 patients with FSHD who will be randomized 1:1 to receive either apitegromab 10mg/kg IV or placebo every 4 weeks for 52 weeks. The primary endpoint is mean lean muscle volume (LMV) change from baseline at 12 months. Secondary endpoints include safety, pharmacokinetics/pharmacodynamics, and mean LMV change from baseline at 6 months. Several exploratory functional endpoints will also be assessed.

SRK-439

SRK-439 is a novel, investigational, subcutaneously administered myostatin inhibitor that binds to pro- and latent myostatin with high affinity and selectivity. Based on preclinical data, SRK-439 has the potential to potently inhibit myostatin and increase muscle mass.

•
Phase 1 study in healthy volunteers ongoing. A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026.

 

Second Quarter 2026 Financial Results

 

Scholar Rock reported a net loss of $109.9 million, including stock-based compensation of $19.7 million, for the quarter ended June 30, 2026, compared to a net loss of $110.0 million, including stock-based

 

 

compensation of $24.4 million, for the quarter ended June 30, 2025. Net loss per common share was $0.84 for the quarter ended June 30, 2026, compared to $0.98 per common share for the quarter ended June 30, 2025.

•
The Company did not record any revenue for the quarters ended June 30, 2026 and 2025.
•
Research and development expense was $58.2 million, including $7.5 million in stock-based compensation, for the quarter ended June 30, 2026, compared to $62.4 million, including $5.8 million in stock-based compensation, for the quarter ended June 30, 2025.
•
General and administrative expense was $50.7 million, including $12.2 million in stock-based compensation, for the quarter ended June 30, 2026, compared to $49.7 million, including $18.6 million in stock-based compensation, for the quarter ended June 30, 2025.
•
As of June 30, 2026, Scholar Rock had cash, cash equivalents, and marketable securities of $492.1 million. This reflects net cash proceeds of $62.8 million from the Company’s at-the-market (ATM) program during the quarter ended June 30, 2026.

 

Conference Call Information

Scholar Rock will host a conference call and webcast today, Thursday, August 6, at 8:00 a.m. ET to review its second quarter 2026 financial results and discuss recent business updates. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com.

To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.

A replay of the webcast will be available on the Company’s website for approximately 90 days.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin programs, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we

 

 

post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials and development programs for apitegromab, including its subcutaneous formulation, SRK-439 and its preclinical programs, and indication selection and development timing, including the timing of any regulatory submissions, decisions and anticipated approvals, the therapeutic potential, clinical benefits and safety of any product candidates, expectations regarding actions by the FDA after its reinspection of the Catalent Indiana facility; the expected timing and outcome of FDA review of the accepted BLA for apitegromab, including the September 30, 2026 PDUFA action date; expectations regarding timing and outcome of EMA review and MAA approval; expectations regarding the availability and timing of commercial supply of apitegromab from Catalent Indiana and a second U.S.-based fill-finish facility, including expected supply from the second fill-finish facility; expectations regarding commercial launch timing, and the achievement of important milestones, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether preclinical and clinical data, including the results from the Phase 3 SAPPHIRE trial and any results from ongoing or future clinical trials, including the Phase 2 OPAL clinical trial, the Phase 2 FORGE trial and the Phase 1 clinical trial of SRK-439, will be sufficient to support regulatory approval or further development; that preclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, data from any ongoing or future trials of apitegromab or data for SRK-439, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; whether the FDA will accept the remediations to the Catalent Indiana fill finish facility in response to the FDA observations, whether the updated BLA, including a second fill finish facility, will be sufficient to support regulatory approval, Scholar Rock’s ability to manage expenses or provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock’s ability to obtain, maintain and protect its intellectual property; and Scholar Rock’s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

 

 

 

 

 

 

Scholar Rock Holding Corporation

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share data)

 

 

 

Three Months Ended June 30,

 

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

 

2026

 

 

2025

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

 

58,234

 

 

$

 

62,401

 

 

$

 

110,048

 

 

$

111,079

 

General and administrative

 

 

 

50,667

 

 

 

 

49,708

 

 

 

 

100,869

 

 

 

78,120

 

Total operating expenses

 

 

 

108,901

 

 

 

 

112,109

 

 

 

 

210,917

 

 

 

189,199

 

Loss from operations

 

 

 

(108,901

)

 

 

 

(112,109

)

 

 

 

(210,917

)

 

 

(189,199

)

Other income (expense), net

 

 

 

(995

)

 

 

 

2,078

 

 

 

 

(4,489

)

 

 

4,445

 

Net loss

 

$

 

(109,896

)

 

$

 

(110,031

)

 

$

 

(215,406

)

 

$

(184,754

)

Net loss per share, basic and diluted

 

$

 

(0.84

)

 

$

 

(0.98

)

 

$

 

(1.67

)

 

$

(1.65

)

Weighted average common shares outstanding, basic and diluted

 

 

 

130,612,734

 

 

 

 

112,703,014

 

 

 

 

128,954,153

 

 

 

112,273,032

 

 

 

Scholar Rock Holding Corporation

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)

 

 

June 30, 2026

 

 

December 31, 2025

 

Assets

 

 

 

 

 

 

Cash, cash equivalents and marketable securities

 

$

492,088

 

 

$

367,563

 

Other current assets

 

 

15,095

 

 

 

17,584

 

Total current assets

 

 

507,183

 

 

 

385,147

 

Other assets

 

 

16,360

 

 

 

19,125

 

Total assets

 

$

523,543

 

 

$

404,272

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current liabilities

 

$

72,242

 

 

$

55,419

 

Long-term liabilities

 

 

197,517

 

 

 

103,365

 

Total liabilities

 

 

269,759

 

 

 

158,784

 

Total stockholders' equity

 

 

253,784

 

 

 

245,488

 

Total liabilities and stockholders' equity

 

$

523,543

 

 

$

404,272

 

 

 

 

 

 

 

 

 

Investors

Laura Ekas, Ph.D.

917-439-0374

ir@scholarrock.com

 

Media

Jeff Smith

682-401-8428

 

Molly MacLeod, Ph.D.

802-579-5995

media@scholarrock.com

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents